PMS17 Long-Term Decrease In Gout Flare Rates Associated With Effective Urate Lowering Therapy  by Kelton, K.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A155
slightly higher disease burden and comorbidities. Factors influencing the observed 
patterns (including the choice of specific biologic for targeted patient profiles) may 
warrant further scrutiny to optimize therapeutic interventions and improve out-
comes.
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OBJECTIVES: Myasthenia Gravis (MG) is an auto immune disease of neuromuscular 
junction, which influences patients’ quality of life (QoL). Studies had showed MG 
patients with poor QoL, but there is no data in Chinese MG patients. METHODS: 
Consecutive MG patients are enrolled in three hospitals in Shenyang, China, from 
July, 2008 to June, 2010. Patients (14≤ age≤ 75 years) with class ‡T, ‡Ua, or ‡Ub MG 
according to Osserman’s classification are enrolled, and are separated into Ocular, 
Mild and Moderate groups. Familial MG, congenital MG and drug-induced MG 
are excluded. QoL is assessed by the SF-36 (rang: 0-100); severity of the disease is 
assessed by Chinese Score for MG (CSMG rang 12-60; higher scores worse weakness). 
Differences are tested using ANOVA and Kruskall-Wallis as appropriate. RESULTS: 
Analysis is based on 248 patients (male 110, 44%; age:46±18 year), of whom 27%, 
35% and 38% classified into Ocular, Mild and Moderated groups respectively. The 
disease history is 47±64 months (median 24). Fifty-nine patients have at least one 
comorbidity, and 71 with thymic hyperplasia, and 49 thymectomy. There is no sig-
nificant difference in demographic characteristics among three groups (P> 0.05), and 
no difference in disease history, comorbidity and treatment either. Ocular group has 
better QoL than Mild and Moderated groups: 64, 57, 51 for each group respectively 
(P= 0.000), and better weakness in CSMG scores: 21, 23, 26 respectively (P= 0.000). 
Significant differences is found in all the subscales of SF-36 among groups (P< 0.05), 
except for general health (P= 0.054), social functioning (P= 0.490), and role-emotional 
(P= 0.104). CONCLUSIONS: Our study reveals that Chinese MG patients have poor 
QoL, and Ocular MG patients have better QoL than those who are Mild and Moderate 
MG, and QoL is influence by the degree of muscle weakness.
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OBJECTIVES: Previous clinical trials have demonstrated that gout patients who 
achieve the target serum urate acid (SUA) level ≤ 6 mg/dL with urate lowering ther-
apy (ULT) experience a reduction in the frequency of gout flares over time. This find-
ing has not been fully exploited in pharmacoeconomic models of ULTs that associate 
constant flare rates with SUA levels. The objective of this study was to quantify the 
long-term rate of decrease in flare frequency among subjects who achieved the tar-
get SUA level in the fEbuXostat/allopurinol Comparative Extension Long-term study 
(EXCEL). METHODS: The EXCEL trial reported the proportion of subjects experienc-
ing ≥ 1 gout flare requiring treatment by two-month intervals. Binomial regression 
was used to fit Gompertz and Weibull survival models to the observations at least 
6 months after baseline, pooled across treatment arms. Model fit was assessed 
by a chi-square test of the model deviance. RESULTS: The goodness of fit test for 
the Gompertz survival model indicated that the model provides an adequate fit to 
the data (model deviance = 14.14 with 15 degrees of freedom; p= .5146). However, 
the goodness of fit test for the Weibull survival model indicated an inadequate 
fit to the data (model deviance = 55.01 with 15 degrees of freedom; p< .0001). The 
maximum likelihood estimate of the shape parameter of the Gompertz survival 
model is -0.0906, where time is measured in months. CONCLUSIONS: The long-
term (≥ 6 months after baseline) gout flare results reported in the EXCEL trial can 
be adequately modeled by a Gompertz survival model, which estimates that the 
gout flare rate decreased by 9.06% per month for subjects who achieved the target 
SUA level of ≤ 6 mg/dL. The results of this analysis may be useful for modeling the 
long-term clinical and economic outcomes of ULTs in patients with gout.
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OBJECTIVES: Evidence supporting the use of anti-osteoporosis (AO) medications 
(AOMs) for preventing fracture among elderly patients with end-stage renal disease 
(ESRD) was scarce. This study evaluated the benefits of AOMs in fracture preven-
tion for elderly patients with ESRD. METHODS: Using 1997-2008 Taiwan’s National 
Health Insurance research database, we identified incident chronic dialysis patients 
with concomitant diagnosis of osteoporosis who had received AOMs during the 
year before dialysis between 1998 and 2007; the AOMs included salmon calcitonin, 
alendronate, zoledronate, raloxifene, and teriparatide. Following the inception of 
dialysis, patients who continued AOMs were categorized into AO treated cohort 
and those who ceased using AOMs were AO untreated cohort. Study outcomes were 
defined as hospitalizations due to hip or vertebral fracture during the follow-up 
period. RESULTS: We identified 490 patients receiving AOMs during the year before 
dialysis. The mean age of AO untreated cohort and AO treated cohort were 74.40 and 
71.64. Fracture hazard risk (HR) in the AO treated cohort was not significantly lower 
than the AO untreated cohort, either unadjusted (HR = 1.02, 95%CI = 0.40-2.62, p = 
0.96) or adjusted (HR = 0.92, 95%CI = 0.30-2.82, p = 0.89). Further analysis in female 
patients resulted in a similar finding. CONCLUSIONS: This study found that use 
of AOMs was not associated with a reduction of fracture risk in elderly chronically 
dialyzed patients.
retrospective medical chart-review of RA patients was conducted to collect de-
identified data for those recently treated with a biologic as part of usual care. 
Physicians (rheumatologists) were screened for duration of practice (3-30yrs) and 
patient volume (incl. > 5 RA biologic patients/month) and recruited from a large 
panel to be geographically representative. Eligible patient charts (≥ 3) were randomly 
selected from a sample of patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
etanercept monotherapy were analyzed. RESULTS: 169 eligible RA patient charts 
were abstracted; 43 on adalimumab (female: 63%, age: 51.7 yrs, average months on 
adalimumab: 39.5, 98% on first biologic) and 63 on etanercept (female: 78%, age: 49.3 
yrs, average months on etanercept: 40.2, 87% on first biologic). Top-3 comorbidites 
(adalimumab vs. etanercept) were obesity: 21% vs. 10%, dyslipidemia: 21% vs. 6% 
and depression/anxiety: 12% vs. 11%. Among patients with available data, latest lab 
measures documented were (adalimumab vs. etanercept): ESR: 26.4 mm/h vs. 23.4 
mm/h, CRP: 2.6 mg/dl vs. 1.7 mg/dl, rheumatoid factor-positive: 84% vs. 73%, and 
anti-CPP-positive: 65% vs. 59%. Latest disease severity measures documented were 
(adalimumab vs. etanercept): Swollen Joint Counts: 1.7 vs. 1.6, Tender Joint Counts: 
2.5 vs. 2.8, and VAS score: 2.4 vs. 2.2. CONCLUSIONS: RA patients on adalimumab 
monotherapy were slightly older and had a lower percentage of female patients than 
those on etanercept. Most (> 85%) were on their first biologic. The adalimumab group 
appeared to have a slightly higher disease burden and comorbidities. Factors influ-
encing the observed patterns (including the choice of specific biologic for targeted 
patient profiles) may warrant further scrutiny to optimize therapeutic interventions 
and improve outcomes.
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OBJECTIVES: Tofacitinib is a new oral drug which has demonstrated efficacy and 
safety in pivotal clinical trials. This study sough to assess the efficacy of tofaci-
tinib in combination with methotrexate compared with biological DMARDs in 
combination with methotrexate, in rheumatoid arthritis (RA) patients with an 
inadequate response to methotrexate. METHODS: We performed an analysis of 
systematic review published in the last five years that assessed biological DMARDs 
(Adalimumab, certolizumab, infliximab, etanercept, golimumab, tocilizumab, rituxi-
mab and abatacept) or tofacitinib to treatment of RA after inadequate response 
to methotrexate. The search was realized in the database of Medline, EMBASE, 
Cochrane, LILACS, DARE and HTA. The data collection was realized by two research-
ers independently. Clinical trials that had been included in the systematic reviews 
were extracted and evaluated their methodological quality with checklist Cochrane. 
With mixed treatment comparison, the effectiveness between biological DMARDs 
and tofacitinib was compared using methotrexate as a common comparator. The 
outcomes considered in terms of effectiveness were improvement rates by ACR20, 
ACR50, ACR70 and HAQ criteria at 12 and 24 weeks. In order to evaluate the impact 
of heterogeneity, we performed analysis of sensibility and subgroups. RESULTS: 
27 systematic reviews were included of which 30 clinical trials were assessed and 
analyzed. The indirect comparison showed that tofacitinib has similar efficacy in 
comparison to biological DMARDs in ACR20, ACR50, ACR70 and HAQ at 12 and 24 
weeks. However, certolizumab displayed better response that tofacitinib in ACR20 
at 12 weeks (OR 0.373 IC 95% 0.201 – 0.615). The sensitivity and subgroup analyses 
by the design of clinical trials, years of disease and number of swollen joint showed 
consistent results. CONCLUSIONS: The mixed treatment comparison indicated that 
tofacitinib is similar in terms of efficacy than biological DMARDs in RA patients with 
an inadequate response to methotrexate.
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OBJECTIVES: To compare the disease status and outcomes of patients with PsA 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A retro-
spective medical chart-review of PsA patients was conducted to collect de-identified 
data for those recently treated with a biologic as part of usual care. Physicians 
(rheumatologists) were screened for duration of practice (3-30yrs) and patient 
volume (incl. > 5 PsA biologic patients/month) and recruited from a large panel 
to be geographically representative. Eligible patient charts (≥ 3) were randomly 
selected from a sample of patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
etanercept monotherapy were analyzed. RESULTS: 84 eligible PsA patient charts 
were abstracted; 37 on adalimumab (male: 54%, age: 46.5 yrs, average months on 
adalimumab: 28.2, 92% on first biologic) and 29 on etanercept (male: 62%, age: 42.3 
yrs, average months on etanercept: 32.2, 100% on first biologic). Top-5 comorbid-
ites (adalimumab vs. etanercept) were obesity: 24% vs. 17%, dyslipidemia: 8% vs. 
7%, diabetes: 8% vs. 3%, kidney disease: 8% vs. 0%, migraine: 3% vs. 3%. Among 
patients with available data, latest lab measures documented were (adalimumab 
vs. etanercept): ESR: 28.0 mm/h vs. 15.8 mm/h and CRP: 3.9 mg/dl vs. 2.3 mg/dl. 
Latest disease severity measures documented were (adalimumab vs. etanercept): 
Swollen Joint Counts: 1.8 vs. 1.1, Tender Joint Counts: 2.6 vs. 3.9, and HAQ rating: 0.7 
vs. 0.3. CONCLUSIONS: PsA patients on adalimumab monotherapy were slightly 
older and on adalimumab for fewer average months than patients on etanercept. 
Most (> 90%) were on their first biologic. The adalimumab group appeared to have a 
